6-Nov-2025 6:30 AM CST - Business Wire Neurogene Announces First Participant Dosed in Embolden Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental diso
8-Oct-2025 6:30 AM CST - Business Wire Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Invest
11-Aug-2025 3:10 PM CST - Business Wire Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement fro
9-May-2025 6:30 AM CST - Business Wire Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year,
24-Mar-2025 3:10 PM CST - Business Wire Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates. We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Rett syndrome, as we reported encouraging interim efficacy data and NGN-401 was generally well-tolerated
24-Feb-2025 6:30 AM CST - Business Wire Neurogene to Participate in Upcoming Conferences Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: TD Cowen 45th Annual Health Care Conference Format: Management will participate in a fireside chat and investor meetings Date: Monday, March 3 at 9:50 a.m. ET Leerink Global Healthcare Conference Format: Management
18-Nov-2024 4:25 PM CST - Business Wire Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates. The recently announced interim data from participants dosed with 1E15 vg in the NGN-401 clinical trial showed consistent improvements across multiple domains that define Rett syndrome, in contrast to what i
11-Nov-2024 3:01 PM CST - Business Wire Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. Low-dose NGN-401 has demonstrated a favorable safe
4-Nov-2024 6:30 AM CST - Business Wire Neurogene Announces Oversubscribed $200 Million Private Placement Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million to Neurogene, before placement agent fees and offering expenses. The oversubscribed PIPE fina
6-Nov-2025 6:30 AM CST - Business Wire Neurogene Announces First Participant Dosed in Embolden Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental diso
8-Oct-2025 6:30 AM CST - Business Wire Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Invest
11-Aug-2025 3:10 PM CST - Business Wire Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement fro
9-May-2025 6:30 AM CST - Business Wire Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year,
24-Mar-2025 3:10 PM CST - Business Wire Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates. We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Rett syndrome, as we reported encouraging interim efficacy data and NGN-401 was generally well-tolerated
24-Feb-2025 6:30 AM CST - Business Wire Neurogene to Participate in Upcoming Conferences Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: TD Cowen 45th Annual Health Care Conference Format: Management will participate in a fireside chat and investor meetings Date: Monday, March 3 at 9:50 a.m. ET Leerink Global Healthcare Conference Format: Management
18-Nov-2024 4:25 PM CST - Business Wire Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates. The recently announced interim data from participants dosed with 1E15 vg in the NGN-401 clinical trial showed consistent improvements across multiple domains that define Rett syndrome, in contrast to what i
11-Nov-2024 3:01 PM CST - Business Wire Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. Low-dose NGN-401 has demonstrated a favorable safe
4-Nov-2024 6:30 AM CST - Business Wire Neurogene Announces Oversubscribed $200 Million Private Placement Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million to Neurogene, before placement agent fees and offering expenses. The oversubscribed PIPE fina
